Who are Haematopoietic growth factor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): GM-CSF and G-CSF, rhG-CSF+rhGM-CSF group, Early receiving G-CSF group, Late receiving G-CSF group, Recombinant Flt3 Ligand, G-CSF+EPO.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/haematopoietic-growth-factor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Haematopoietic growth factor — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Haematopoietic growth factor (Haematopoietic growth factor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hematopoietic growth factor. Area: Hematology/Oncology.

phase 3 Hematopoietic growth factor Hematology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Haematopoietic growth factor (Haematopoietic growth factor) — University College, London. Haematopoietic growth factors stimulate the bone marrow to produce and release blood cells, including red blood cells, white blood cells, and platelets.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Haematopoietic growth factor TARGET	Haematopoietic growth factor	University College, London	phase 3	Hematopoietic growth factor
GM-CSF and G-CSF	GM-CSF and G-CSF	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	marketed	Hematopoietic growth factor	GM-CSF receptor (CD116) and G-CSF receptor (CD114)
rhG-CSF+rhGM-CSF group	rhG-CSF+rhGM-CSF group	Xiamen Amoytop Biotech Co., Ltd.	marketed	Hematopoietic growth factor combination	G-CSF receptor; GM-CSF receptor
Early receiving G-CSF group	Early receiving G-CSF group	Department of Medical Services Ministry of Public Health of Thailand	marketed	Cytokine; Hematopoietic growth factor	G-CSF receptor (GCSFR)
Late receiving G-CSF group	Late receiving G-CSF group	Department of Medical Services Ministry of Public Health of Thailand	marketed	Cytokine; Hematopoietic growth factor	G-CSF receptor (GCSFR)
Recombinant Flt3 Ligand	Recombinant Flt3 Ligand	University of Southern California	phase 3	Cytokine; Hematopoietic growth factor	Flt3 receptor (FLT3)
G-CSF+EPO	G-CSF+EPO	Institute of Liver and Biliary Sciences, India	phase 3	Hematopoietic growth factor combination	G-CSF receptor (GCSFR) and Erythropoietin receptor (EPOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hematopoietic growth factor class)

University College, London · 1 drug in this class
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Haematopoietic growth factor — Competitive Intelligence Brief. https://druglandscape.com/ci/haematopoietic-growth-factor. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab